Evidence map›Paper›PMID 39557840›Full record

ReviewCell death & disease2024

New insights into crosstalk between Nrf2 pathway and ferroptosis in lung disease.

Yonghu Chen, Zhe Jiang, Xuezheng Li

Abstract readReview
In one paragraph

Review in Cell death & disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Nanozyme-Driven Ferroptosis-Cuproptosis Interplay in Lung Cancer.International journal of nanomedicine · 2026
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yonghu ChenCollege of Pharmacy, Yanbian University Hospital, Yanbian University, Yanji, 133002, P. R. China.
Zhe JiangCollege of Pharmacy, Yanbian University Hospital, Yanbian University, Yanji, 133002, P. R. China. jiangz@ybu.edu.cn.
Xuezheng LiCollege of Pharmacy, Yanbian University Hospital, Yanbian University, Yanji, 133002, P. R. China. xzli@ybu.edu.cn.ORCID 0000-0002-2276-7590

Funding

Jilin Department of Health (Department of Health, Jilin Province) 2023JC028National Natural Science Foundation of China (National Science Foundation of China) 82260820Natural Science Foundation of Jilin Province (Natural Science Foundation of Jilin Province of China) YDZJ202201ZYTS155
6 · The paper itself

Abstract

Ferroptosis is a distinctive process of cellular demise that is linked to amino acid metabolism, lipid oxidation, and iron oxidation. The ferroptosis cascade genes, which are closely associated with the onset of lung diseases, are among the regulatory targets of nuclear factor erythroid 2-related factor 2 (Nrf2). Although the regulation of ferroptosis is mostly mediated by Nrf2, the precise roles and underlying regulatory mechanisms of ferroptosis and Nrf2 in lung illness remain unclear. This review provides new insights from recent discoveries involving the modulation of Nrf2 and ferroptosis in a range of lung diseases. It also systematically describes regulatory mechanisms involving lipid peroxidation, intracellular antioxidant levels, ubiquitination of Nrf2, and expression of FSP1 and GPX4. Finally, it summarises active ingredients and drugs with potential for the treatment of lung diseases. With the overarching aim of expediting improvements in treatment, this review provides a reference for novel therapeutic mechanisms and offers suggestions for the development of new medications for a variety of lung disorders.

Indexed as

FerroptosisLung DiseasesNF-E2-Related Factor 2Signal TransductionAnimalsHumansLipid PeroxidationNF-E2-Related Factor 2

Identifiers

PMID39557840
PMCPMC11574213

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.